Type 1 Narcolepsy (NT1)

Previously: Narcolepsy with Cataplexy

Diagnostic Criteria (Either criterion):

• Excessive daytime sleepiness PLUS cataplexy, OR
• Cerebrospinal fluid (CSF) hypocretin-1 levels ≤110 pg/mL or <1/3 of normal controls

Key Features:

• Nearly always includes cataplexy (though may develop years after sleepiness)
• Extremely low or undetectable hypocretin levels (in >90% of cases)
• Loss of 80-90% of hypocretin-producing neurons
• More severe and disabling symptoms
• Strong genetic association (HLA DQB1*0602 positive in 95%)
• REM sleep intrusions during wakefulness

MSLT Findings:

• Mean sleep latency ≤8 minutes
• ≥2 sleep-onset REM periods (SOREMPs) in 5 naps

Prevalence: About 65-75% of narcolepsy cases

Type 2 Narcolepsy (NT2)

Previously: Narcolepsy without Cataplexy

Diagnostic Criteria (All required):

• Excessive daytime sleepiness
• NO cataplexy
• MSLT showing mean sleep latency ≤8 min AND ≥2 SOREMPs
• Normal CSF hypocretin-1 levels (>110 pg/mL) OR not measured

Key Features:

• Excessive daytime sleepiness but no cataplexy
• Hypocretin levels usually normal (though ~30% have low levels)
• Possibly less severe hypocretin neuron loss
• May be a milder or early form of Type 1
• About 1/3 with low hypocretin may develop cataplexy later
• Less severe overall symptom burden
• Weaker HLA association

Diagnostic Challenges:

• MSLT less reliable/repeatable in NT2
• May overlap with idiopathic hypersomnia
• Diagnosis may evolve to NT1 if cataplexy develops

Prevalence: About 25-35% of narcolepsy cases

Secondary Narcolepsy

Definition: Narcolepsy-like symptoms resulting from identifiable brain injury or disease affecting the hypothalamus.

Causes:

• Brain tumors affecting hypothalamus
• Head trauma
• Stroke or vascular disorders
• Multiple sclerosis
• Encephalitis or brain infections
• Paraneoplastic syndromes
• Neurodegenerative diseases
• Genetic/congenital disorders

Unique Features:

• Identifiable structural lesion or disease process
• May have additional neurological symptoms
• Sleep duration often >10 hours/night
• Variable hypocretin levels
• Not necessarily HLA-associated
• May be reversible if underlying cause treated

1. Excessive Daytime Sleepiness (EDS)

Present in 100% of Cases

Characteristics:

• Overwhelming, irresistible sleepiness during the day
• Sudden "sleep attacks" - falling asleep without warning
• Brief, refreshing naps (10-20 minutes) provide temporary relief
• Sleepiness returns within 1-3 hours after nap
• Occurs during inappropriate times (conversations, eating, driving, working)
• Unlike normal tiredness - cannot be "fought off"
• Most debilitating symptom for many patients

Impact:

• Impairs academic/work performance
• Dangerous while driving or operating machinery
• Mistaken for laziness or lack of motivation
• Severely reduces quality of life

2. Cataplexy

Specific to Type 1 (60-75% of patients)

Definition: Sudden, brief episodes of bilateral muscle weakness or paralysis triggered by strong emotions while fully conscious.

Emotional Triggers:

• Laughter (most common - 90% of cases)
• Surprise or being startled
• Anger or frustration
• Excitement or joy
• Pride
• Rarely: sadness or fear

Physical Manifestations:

• Mild: Facial sagging, jaw drop, head drooping, knee buckling, slurred speech
• Moderate: Arm weakness, dropping objects, sitting down
• Severe: Complete body collapse, falling
• Eyes may flutter or close involuntarily
• Speech may become unintelligible

Key Features:

• Duration: Typically seconds to 2 minutes
• Consciousness preserved throughout
• No loss of awareness
• Breathing continues normally
• Complete recovery with no confusion
• Frequency: Can occur rarely to dozens of times daily

Social Impact:

• Patients may avoid emotions/social situations
• Risk of injury from falls
• Embarrassment and social withdrawal
• Most specific diagnostic marker for narcolepsy

3. Sleep Paralysis

Occurs in 25-50% of Patients

Description:

• Brief inability to move or speak when falling asleep or waking up
• Consciousness preserved - fully aware but unable to move
• Can breathe normally but may feel chest pressure
• May be accompanied by visual/auditory hallucinations
• Duration: Typically seconds to few minutes
• Ends spontaneously or with touch from another person

Experience:

• Can be extremely frightening, especially first occurrence
• Feeling of presence in room
• Sense of impending doom
• Complete paralysis except eye movements
• Relief when episode ends

Note: Sleep paralysis also occurs in 5-10% of general population without narcolepsy, especially with sleep deprivation.

4. Hypnagogic/Hypnopompic Hallucinations

Occurs in 30-80% of Patients

Definitions:

• Hypnagogic: Hallucinations when falling asleep
• Hypnopompic: Hallucinations when waking up

Types of Hallucinations:

• Visual: Seeing people, animals, objects, shadows (most common)
• Auditory: Hearing voices, music, noises
• Tactile: Feeling touched, insects crawling
• Complex: Multi-sensory dreamlike experiences

Characteristics:

• Extremely vivid and realistic
• Can be frightening or bizarre
• Often incorporates actual environment
• May occur with sleep paralysis
• Brief duration (seconds to minutes)

Mechanism: REM sleep dream imagery intruding into wakefulness or sleep onset

5. Disrupted Nighttime Sleep

Occurs in 70-90% of Patients

Paradox: Despite overwhelming daytime sleepiness, nighttime sleep is often fragmented and poor quality.

Nighttime Sleep Problems:

• Frequent awakenings throughout night
• Difficulty staying asleep
• Waking feeling unrefreshed
• Sleep fragmentation
• REM sleep occurring at inappropriate times
• Vivid, intense dreams or nightmares
• Periodic limb movements (30-50% of patients)
• Sleep talking or acting out dreams

Impact:

• Compounds daytime sleepiness
• Reduces total sleep quality despite normal or increased sleep duration
• May be mistaken for insomnia

Additional Common Symptoms

Automatic Behaviors (40-80%):

• Performing routine tasks while partially asleep
• No memory of actions afterward
• Writing illegible notes, putting items in wrong places
• Continuing conversations without awareness
• Can last seconds to minutes

Cognitive & Mental Health:

• Memory problems and difficulty concentrating
• Depression (common - may be reactive or independent)
• Anxiety (especially social anxiety)
• Mood swings and irritability
• Reduced processing speed

Other Associations:

• Weight gain and obesity (despite low caloric intake in some)
• Premature puberty in children
• Metabolic changes
• Increased risk of other sleep disorders (OSA, PLMD)

Autoimmune Mechanism (Primary Theory)

Evidence for Autoimmune Origin:

• Strong HLA association (HLA DQB1*0602 in 95% of Type 1)
• Selective loss of specific neuron type (hypocretin cells)
• Triggering by infections (particularly H1N1 influenza, strep throat)
• Association with H1N1 vaccine (Pandemrix) in some cases
• Onset pattern consistent with autoimmune disorders

Proposed Mechanism:

• Immune system mistakenly attacks and destroys hypocretin neurons
• Molecular mimicry - infection triggers cross-reactive antibodies
• Targets limited to 100,000-200,000 hypocretin neurons in hypothalamus
• Progressive cell death over months to years

Challenges to Autoimmune Theory:

• No specific auto-antibodies consistently identified
• No evidence of active inflammation in brain tissue
• Immunosuppression trials have shown mixed results
• Exact immune mechanism remains unclear

Genetic Factors

HLA Association:

• HLA DQB1*0602 present in 95% of Type 1 narcolepsy
• Also found in 12-38% of general population (low specificity)
• Increases risk 10-20 fold but not sufficient alone
• Type 2 has weaker HLA association (~40%)

Family History:

• 1-2% of first-degree relatives develop narcolepsy
• Concordance in identical twins: only 25-31%
• Suggests genetic predisposition + environmental trigger needed

Rare Genetic Causes:

• Mutations in hypocretin gene (extremely rare in humans)
• Mutations in hypocretin receptor genes (found in dogs, not confirmed in humans)
• May account for some familial cases

Environmental Triggers

Infections:

• H1N1 Influenza (2009 pandemic): Marked increase in narcolepsy onset
• Streptococcal infections: Strep throat associated with onset
• Other viral infections: Various respiratory viruses implicated
• Mechanism: Molecular mimicry triggering autoimmune response

Vaccinations (Controversial):

• Pandemrix H1N1 vaccine (Europe, 2009-2010) associated with increased incidence
• Particularly in children and adolescents
• Other H1N1 vaccines did not show same association
• Risk-benefit analysis favored vaccination despite rare cases

Other Potential Triggers:

• Head trauma
• Hormonal changes (puberty, pregnancy)
• Significant stress
• Sudden change in sleep schedule

Excessive Daytime Sleepiness Mechanism

Sleep-Wake Instability:

• Loss of hypocretin reduces activity of wake-promoting neurons
• Brain cannot sustain prolonged wakefulness
• Thresholds between wake and sleep easily crossed
• Results in "sleep state instability"
• Fragmented wakefulness with intrusions of sleep

Why Brief Naps Help:

• Temporarily reduces sleep drive
• Effect lasts 1-3 hours before sleepiness returns
• Unlike normal sleep, doesn't provide sustained alertness

Cataplexy Mechanism

Unique to Hypocretin Deficiency:

• REM sleep muscle atonia (paralysis) intrudes into wakefulness
• Normally, hypocretin neurons counteract emotion-triggered inhibition of muscle tone
• Without hypocretin, strong emotions trigger unchecked muscle tone loss

Brain Circuit Dysregulation:

• Emotional stimuli activate amygdala and limbic system
• These normally briefly inhibit norepinephrine neurons
• Hypocretin normally provides excitatory drive to counterbalance
• Without hypocretin: unchecked norepinephrine inhibition → muscle paralysis
• Activates medullary inhibitory neurons → glycine/GABA release → muscle atonia

Why Laughter Triggers It:

• Positive emotions (especially laughter) create strongest limbic activation
• Most potent trigger for norepinephrine cell inhibition
• Explains why laughter is most common cataplexy trigger

REM Sleep Dysregulation

Normal REM Control Lost:

• Hypocretin normally suppresses REM sleep during wake
• Coordinates REM timing with circadian rhythms
• Without hypocretin: REM occurs at inappropriate times

Consequences:

• Sleep-Onset REM Periods (SOREMPs): Entering REM within 15 min of sleep onset (vs. normal 90+ min)
• Hypnagogic/Hypnopompic Hallucinations: REM dream imagery during wake-sleep transitions
• Sleep Paralysis: REM muscle atonia persisting into wakefulness
• Fragmented Nighttime Sleep: REM dysregulation disrupts normal sleep architecture

Clinical Evaluation

Medical History:

• Detailed sleep history and symptom timeline
• Description of sleepiness severity and pattern
• Presence/description of cataplexy episodes
• Sleep paralysis and hallucinations
• Nighttime sleep quality
• Family history of narcolepsy or sleep disorders
• Recent infections or vaccinations
• Impact on work, school, driving, relationships

Sleep Diary:

• Track sleep-wake patterns for 1-2 weeks
• Document naps, nighttime sleep, sleepiness episodes

Questionnaires:

• Epworth Sleepiness Scale (ESS): Scores >10 indicate excessive sleepiness
• Stanford Sleepiness Scale
• Narcolepsy-specific symptom questionnaires

Multiple Sleep Latency Test (MSLT)

Gold Standard for Diagnosis

Procedure:

• Performed day after overnight polysomnography
• Five scheduled 20-minute nap opportunities at 2-hour intervals
• Patient lies in dark, quiet room and instructed to try to fall asleep
• Monitoring continues for 15 min after sleep onset or full 20 min if no sleep
• Patient must be off certain medications (stimulants, antidepressants) for 2 weeks

Measurements:

• Mean Sleep Latency: Average time to fall asleep across 5 naps
• Sleep-Onset REM Periods (SOREMPs): Number of naps where REM occurs within 15 min of sleep onset

Diagnostic Criteria:

• Mean sleep latency ≤8 minutes (normal >10 min)
• ≥2 SOREMPs in 5 naps (can include SOREMP from overnight PSG)

Limitations:

• High night-to-night variability, especially in Type 2
• Only ~50-60% reproducibility in Type 2 on retest
• Can be affected by medications, sleep deprivation, circadian disorders
• False positives possible with OSA, shift work, depression

Polysomnography (Overnight Sleep Study)

Purpose:

• Performed night before MSLT
• Ensures adequate sleep (≥6 hours) for valid MSLT
• Rules out other sleep disorders (OSA, PLMD, REM sleep behavior disorder)
• May show SOREMP (counts as 1 toward MSLT criteria)
• Documents sleep fragmentation

Findings in Narcolepsy:

• SOREMP in 40-50% of patients
• Frequent awakenings and arousals
• REM sleep abnormalities
• Increased stage 1 sleep
• May show coexisting sleep disorders

CSF Hypocretin-1 Testing

Highly Specific for Type 1

Procedure:

• Lumbar puncture (spinal tap) to collect cerebrospinal fluid
• Measures hypocretin-1 (orexin-A) levels
• Specialized test, not widely available

Interpretation:

• ≤110 pg/mL (or <1/3 normal): Diagnostic for Type 1 narcolepsy
• >110 pg/mL: Type 2 or other hypersomnia
• 90-95% of Type 1 have low/undetectable levels
• ~30% of Type 2 have low levels (may develop cataplexy later)

Advantages:

• Highly specific and sensitive for Type 1
• Not affected by medications
• Can diagnose without MSLT in clear cases
• Useful when MSLT equivocal

Limitations:

HLA Typing

HLA DQB1*0602 Testing:

• Blood test for genetic marker
• Present in 95% of Type 1 narcolepsy
• Also in 12-38% of general population

Clinical Use:

• High Sensitivity: Negative test makes Type 1 unlikely
• Low Specificity: Positive test doesn't confirm diagnosis
• Helpful in ambiguous cases
• Supportive evidence, not diagnostic alone

Differential Diagnosis

Other Conditions to Exclude:

• Sleep Disorders: OSA, idiopathic hypersomnia, insufficient sleep syndrome, circadian rhythm disorders
• Medical: Hypothyroidism, anemia, chronic fatigue syndrome, Kleine-Levin syndrome
• Psychiatric: Depression, bipolar disorder, atypical depression
• Neurological: Multiple sclerosis, myasthenia gravis (for cataplexy), brain tumors
• Medications: Sedating medications, withdrawal from stimulants

Medications for Excessive Daytime Sleepiness

Modafinil/Armodafinil (First-Line):

• Wake-promoting agents
• Modafinil (Provigil): 100-400 mg/day, usually in morning
• Armodafinil (Nuvigil): 150-250 mg/day
• Improves EDS by 65-90%
• Lower abuse potential than traditional stimulants
• Side effects: Headache, nausea, anxiety
• Well-tolerated, first choice for most patients

Solriamfetol (Sunosi):

• Dopamine-norepinephrine reuptake inhibitor
• 75-150 mg upon awakening
• Very effective for EDS
• Approved 2019
• Side effects: Headache, nausea, anxiety, increased blood pressure

Pitolisant (Wakix):

• Histamine H3 receptor antagonist
• Enhances histamine release
• Also reduces cataplexy
• Lower abuse potential
• 17.8-35.6 mg/day

Traditional Stimulants (Second-Line):

• Methylphenidate (Ritalin, Concerta): 10-60 mg/day
• Amphetamine salts (Adderall): 5-60 mg/day
• Dextroamphetamine
• More side effects: Irritability, headache, palpitations, hypertension
• Controlled substances (Schedule II)
• Risk of tolerance, dependence
• Used if first-line medications inadequate

Medications for Cataplexy

Sodium Oxybate (Xyrem, Xywav) - First-Line:

• Sodium salt of gamma-hydroxybutyrate (GHB)
• ONLY medication approved specifically for cataplexy
• Also improves EDS and nighttime sleep
• Taken twice nightly (at bedtime and 2.5-4 hours later)
• Dose: 4.5-9 g/night total, divided into two doses
• Highly effective: reduces cataplexy by 70-90%

Benefits:

• Reduces/eliminates cataplexy
• Improves daytime sleepiness
• Consolidates nighttime sleep
• Reduces sleep paralysis and hallucinations
• May work when other treatments fail

Important Restrictions:

• DEA Schedule III controlled substance
• Risk Evaluation and Mitigation Strategy (REMS) program required
• Central pharmacy distribution only
• Requires patient/prescriber enrollment
• Cannot combine with alcohol or sedatives

Side Effects:

• Nausea (most common)
• Dizziness, headache
• Bedwetting (enuresis) in children
• Weight loss
• Sleepwalking or sleep-related behaviors
• Depression or suicidal ideation (monitor closely)

Antidepressants (Off-Label):

• SSRIs: Fluoxetine, sertraline, citalopram
• SNRIs: Venlafaxine, duloxetine
• TCAs: Clomipramine, imipramine, protriptyline (very effective but more side effects)
• Suppress REM sleep, reduce cataplexy
• Less effective than sodium oxybate
• May cause rebound cataplexy if stopped suddenly
• Can worsen nighttime sleep

Combination Therapy

Common Combinations:

• Modafinil + Sodium Oxybate (very common and effective)
• Stimulant + Antidepressant (for cataplexy)
• Sodium Oxybate alone may control all symptoms

Advantages:

• Targets multiple symptoms
• May allow lower doses of each medication
• Sodium oxybate at night + wake-promoting agent during day
• Individualized based on symptom profile

Work & School Accommodations

Americans with Disabilities Act (ADA):

• Narcolepsy qualifies as disability
• Employers must provide reasonable accommodations
• Schools must provide accommodations under Section 504/IDEA

Workplace Accommodations:

• Flexible work schedule
• Permission for scheduled nap breaks
• Quiet place to nap
• Modified duties if job safety-sensitive
• Work from home options
• Avoid shift work

School Accommodations:

• Extended time on tests
• Scheduled nap periods
• Excused absences for medical appointments
• Note-taking assistance
• Reduced course load if needed
• Late start times

Driving & Safety

Driving Restrictions:

• Vary by state/country
• Some require physician clearance
• Should not drive until symptoms well-controlled
• May require symptom-free period documentation
• Regular monitoring required

Safety Guidelines:

• Pull over immediately if feeling sleepy
• Take strategic nap before long drives
• Avoid driving during known sleepy periods
• Use public transportation when possible
• Inform insurance company

Emotional & Social Support

Common Challenges:

• Misunderstood as lazy or unmotivated
• Social isolation
• Depression and anxiety common
• Relationship difficulties
• Embarrassment from cataplexy or sleep attacks

Support Resources:

• Narcolepsy Network (patient advocacy organization)
• Project Sleep / Wake Up Narcolepsy
• Support groups (in-person and online)
• Mental health counseling
• Family education important

Sleep Resources

• Stages of Sleep & Dreams
• Insomnia Disorder
• Obstructive Sleep Apnea
• Sleep Disorders Overview

Professional Organizations & Support

• Narcolepsy Network (narcolepsynetwork.org)
• Project Sleep / Wake Up Narcolepsy
• Hypersomnia Foundation
• American Academy of Sleep Medicine
• National Sleep Foundation